可行性及初步结果:氟昔洛韦正电子发射断层扫描/超声融合靶向活检用于复发性前列腺癌
研究评估了氟昔洛韦(18F)正电子发射断层扫描-超声融合靶向活检在非手术治疗后生化失败的前列腺癌患者中的可行性和癌症检出率,并与标准模板活检进行自身对照。21例患者中,靶向活检检出10例(47.6%)阳性,模板活检检出6例(28.6%)阳性,靶向活检用更少针道检出更多复发性前列腺癌。结论认为融合引导活检可行,需进一步研究确定靶向活检如何补充模板活检。
要点
- 氟昔洛韦PET/超声融合靶向活检在非手术治疗后生化失败的前列腺癌患者中可行。
- 同一患者中,靶向活检检出10/21例(47.6%),模板活检检出6/21例(28.6%)。
- 靶向活检用更少针道(125针 vs 246针)检出更多复发性前列腺癌。
核心结论
- 氟昔洛韦正电子发射断层扫描实时超声融合引导活检在非手术治疗后生化失败的前列腺癌患者中可行,且与模板活检相比,在同一患者中用更少针道检出更多复发性前列腺癌,需进一步研究确定靶向活检如何补充模板活检。
研究设计与样本
- 自身对照研究,纳入21例非手术治疗后生化失败的前列腺癌患者,平均±标准差前列腺特异性抗原为7.4±6.8 ng/ml,均接受氟昔洛韦(18F)正电子发射断层扫描-计算机断层扫描(平均364.1±37.7 MBq)及计划性经直肠前列腺超声三维图像重建,随后行计算机生成的12针模板活检和氟昔洛韦定义靶向活检。
主要发现
- 模板活检在6/21例(28.6%)患者中阳性,包括124个区域中的10个和246针中的11针;靶向活检在10/21例(47.6%)中阳性,包括50个区域中的17个和125针中的40针。
- 5/21例患者仅靶向活检阳性,1/21例仅模板活检阳性。
- 1例靶向活检使分级组从2级升级为3级。
- 8/21例(38.1%)检出前列腺外病变,其中3例接受病灶活检者均获组织学确认。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究确定靶向活检以何种方式补充复发性前列腺癌的模板活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed the feasibility and cancer detection rate of fluciclovine (18F) positron emission tomography-ultrasound fusion targeted biopsy vs standard template biopsy in the same patient with biochemical failure after nonsurgical therapy for prostate cancer. MATERIALS AND METHODS: A total of 21 patients with a mean ± SD prostate specific antigen of 7.4 ± 6.8 ng/ml and biochemical failure after nonoperative prostate cancer treatment underwent fluciclovine (18F) positron emission tomography-computerized tomography (mean 364.1 ± 37.7 MBq) and planning transrectal prostate ultrasound with 3-dimensional image reconstruction. Focal prostatic activity on positron emission tomography was delineated and co-registered with planning ultrasound. During the subsequent biopsy session computer generated 12-core template biopsies were performed and then fluciclovine defined targets were revealed and biopsied. Histological analysis of template and targeted cores were completed. RESULTS: Template biopsy was positive for malignancy in 6 of 21 patients (28.6%), including 10 of 124 regions and 11 of 246 cores, vs targeted biopsy in 10 of 21 (47.6%), including 17 of 50 regions and 40 of 125 cores. Five of 21 patients had positive findings on targeted biopsy only and 1 of 21 had positive findings on template biopsy only. An additional case was upgraded from Grade Group 2 to 3 on targeted biopsy. Extraprostatic disease was detected in 8 of 21 men (38.1%) with histological confirmation in all 3 who underwent lesion biopsy. CONCLUSIONS: Fluciclovine positron emission tomography real-time ultrasound fusion guidance for biopsy is feasible in patients with biochemical failure after nonsurgical therapy for prostate cancer. It identifies more recurrent prostate cancer using fewer cores compared with template biopsy in the same patient. Further study is required to determine in what manner targeted biopsy may augment template biopsy of recurrent prostate cancer.
引用
- Fei B, Abiodun-Ojo OA, Akintayo AA, et al. Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer. J Urol. 2019. PMID: 30817240. doi:10.1097/JU.0000000000000200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。